Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA OTCMKTS:CSLLY NYSE:GSK NYSE:GSK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.04+2.5%$1.35$0.88▼$4.08$277.65M0.353.50 million shs3.13 million shsCSLLYCSL$17.77-0.2%$23.07$17.06▼$44.86$34.03B0.69419,611 shs284,993 shsGSKGSK$51.36+1.1%$54.07$35.45▼$61.69$104.24B0.384.97 million shs830,978 shsGSKGSK$51.36+1.1%$54.07$35.45▼$61.69$104.24B0.384.97 million shs830,978 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+12.84%-14.41%-29.37%-14.41%-65.41%CSLLYCSL+2.47%+0.11%-28.04%-67.03%-77.26%GSKGSK-0.54%-0.33%-11.41%-16.57%+32.30%GSKGSK-0.54%-0.33%-11.41%-16.57%+32.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.04+2.5%$1.35$0.88▼$4.08$277.65M0.353.50 million shs3.13 million shsCSLLYCSL$17.77-0.2%$23.07$17.06▼$44.86$34.03B0.69419,611 shs284,993 shsGSKGSK$51.36+1.1%$54.07$35.45▼$61.69$104.24B0.384.97 million shs830,978 shsGSKGSK$51.36+1.1%$54.07$35.45▼$61.69$104.24B0.384.97 million shs830,978 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+12.84%-14.41%-29.37%-14.41%-65.41%CSLLYCSL+2.47%+0.11%-28.04%-67.03%-77.26%GSKGSK-0.54%-0.33%-11.41%-16.57%+32.30%GSKGSK-0.54%-0.33%-11.41%-16.57%+32.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.20Hold$4.67350.89% UpsideCSLLYCSL 1.75ReduceN/AN/AGSKGSK 1.90Reduce$53.003.20% UpsideGSKGSK 1.90Reduce$53.003.20% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, CSLLY, GSK, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026CSLLYCSL Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/11/2026CSLLYCSL Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/11/2026CSLLYCSL CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/6/2026AKBAAkebia Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/6/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/1/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B)5/1/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B)4/7/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/7/2026AKBAAkebia Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/19/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)3/19/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$236.20M1.18N/AN/A$0.10 per share10.35CSLLYCSL$15.56B2.19$2.23 per share7.95$11.05 per share1.61GSKGSK$43.07B2.42$6.04 per share8.50$11.57 per share4.44GSKGSK$43.07B2.42$6.04 per share8.50$11.57 per share4.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)CSLLYCSL$3.00BN/AN/A10.453.10N/AN/AN/AN/AGSKGSK$7.54B$3.8513.3510.012.6117.82%44.28%11.49%7/29/2026 (Estimated)GSKGSK$7.54B$3.8513.3510.012.6117.82%44.28%11.49%7/29/2026 (Estimated)Latest AKBA, CSLLY, GSK, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AKBAAkebia Therapeutics-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million2/26/2026Q4 2025AKBAAkebia Therapeutics-$0.03-$0.05-$0.02-$0.05$48.37 million$57.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACSLLYCSL$0.593.32%N/AN/AN/AGSKGSK$1.813.52%-7.86%47.01%N/AGSKGSK$1.813.52%-7.86%47.01%N/ALatest AKBA, CSLLY, GSK, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GSKGSKquarterly$0.443.71%5/15/20265/15/20267/9/20264/29/2026GSKGSKquarterly$0.443.71%5/15/20265/15/20267/9/20261/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/20251/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.331.401.33CSLLYCSL0.512.571.15GSKGSK0.800.790.52GSKGSK0.800.790.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CSLLYCSL0.03%GSKGSK15.74%GSKGSK15.74%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics4.30%CSLLYCSLN/AGSKGSK10.00%GSKGSK10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430268.26 million256.72 millionOptionableCSLLYCSL29,9041.92 billionN/ANot OptionableGSKGSK66,8412.03 billion1.83 billionOptionableGSKGSK66,8412.03 billion1.83 billionOptionableAKBA, CSLLY, GSK, and GSK HeadlinesRecent News About These CompaniesGSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?1 hour ago | zacks.comGSK and the pan-Canadian Pharmaceutical Alliance (pCPA) initiate negotiations for Blenrep for the treatment of relapsed or refractory multiple myelomaMay 20 at 9:59 AM | finance.yahoo.comBroker tips: AstraZeneca, GSK, Oxford InstrumentsMay 19 at 8:28 AM | sharecast.comSGSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased riskMay 19 at 8:28 AM | pharmabiz.comPWall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend YieldsMay 19 at 8:24 AM | benzinga.comGSK signs agreement with Protas to streamline clinical trialsMay 18 at 9:33 AM | pmlive.comPHSBC, BP and GSK combine in dividend-driven knock to FootsieMay 14, 2026 | proactiveinvestors.co.ukGSK India's growth shifts to cancer therapies and adult vaccinesMay 13, 2026 | msn.comGSK Pharma declares bumper dividend of Rs 57/share on Q4 profit, revenue uptick — check record dateMay 13, 2026 | msn.comGSK and SBP Group team up to advance bepirovirsen launch in ChinaMay 12, 2026 | finance.yahoo.comGSK inks hepatitis B collaboration with Sino BioMay 12, 2026 | thepharmaletter.comTGSK plc (GSK) Shareholder/Analyst Call - SlideshowMay 12, 2026 | seekingalpha.comGSK China Hepatitis B Alliance Puts Bepirovirsen And Valuation In FocusMay 12, 2026 | finance.yahoo.comPharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of BepirovirsenMay 11, 2026 | pharmexec.comPGSK cuts deal with Sino to broaden reach of hepatitis B drugMay 11, 2026 | finance.yahoo.comGSK targets China's hepatitis B market through new dealMay 11, 2026 | msn.comGSK to team up with Sino Biopharma for China launch of hepatitis B treatmentMay 11, 2026 | reuters.com129,513 Shares in GSK PLC Sponsored ADR $GSK Acquired by PFA Pension ForsikringsaktieselskabMay 5, 2026 | marketbeat.comA Look At GSK (LSE:GSK) Valuation After Recent Share Price Weakness And Pipeline DevelopmentsMay 3, 2026 | finance.yahoo.comGSK (GSK) Completes $950M Acquisition to Expand Drug PipelineMay 3, 2026 | finance.yahoo.comGSK Juggles Alzheimer’s Setback And Leadership Shift With Product ProgressMay 2, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026AKBA, CSLLY, GSK, and GSK Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$1.03 +0.03 (+2.48%) As of 12:35 PM Eastern This is a fair market value price provided by Massive. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CSL OTCMKTS:CSLLY$17.77 -0.04 (-0.25%) As of 12:18 PM EasternCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.GSK NYSE:GSK$51.36 +0.58 (+1.14%) As of 12:35 PM Eastern This is a fair market value price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.GSK NYSE:GSK$51.36 +0.58 (+1.14%) As of 12:35 PM Eastern This is a fair market value price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Corpay’s Quiet Strength Is Winning Wall Street Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
